Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Epanova

(omega-3-carboxylic acids, 2g)

Small molecule

0

Indications

1

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

4

Patents

Clinical

Trials by Indication[1]

Unspecified1 trial

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01408303·646 enrolled

Regulatory

FDA Approval Timeline[3]

May 5, 2014

EPANOVA

NDA NDA205060

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for omega-3-carboxylic acids, 2g. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — omega-3-carboxylic acids, 2g compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA205060). U.S. Food & Drug Administration.
[4]
FDA Orange Book — Patent and exclusivity data for Epanova. U.S. Food & Drug Administration.
[5]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AstraZeneca

Patent Landscape[4]

Patent Cliff

Dec 20, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7960370Dec 20, 2026

10117844Jan 4, 2033

9050308Jan 4, 2033

9050309Jan 4, 2033

Related News